Raphael Stevens

American briefly grounded U.S. flights on Tuesday.
The carrier said a technical problem stemmed from a hardware issue with a third-party platform.
The ground stop lasted about one hour but more than 900 American flights were delayed.

American Airlines planes sit by their gates at the Miami International Airport on October 25, 2024 in Miami, Florida.
Joe Raedle | Getty Images

American Airlines briefly grounded its U.S. flights Tuesday morning due to a technical problem, snarling travel during what carriers expect to be a period of record demand for the holidays.
By 7:55 a.m. ET, the ground stop had been lifted, an American Airlines spokeswoman told CNBC. The ground stop lasted for less than an hour but more than 900 American Airlines mainline flights had been delayed, according to flight-tracking site FlightAware. That was more than 38% of American’s schedule for Tuesday, and more delays than any other U.S. carrier. Only 11 mainline flights were canceled, however.

The airline’s subsidiary regional carrier Envoy also reported another 200 delayed flights. In addition to the earlier ground stop, American was also facing thunderstorms in the Dallas-Fort Worth area, where its biggest hub is located.
The problem was a network hardware issue involving a platform using DXC Technology, a vendor that maintains the flight operating system that lets flights leave the gate, American said in a statement.
The system is tied to critical data like an aircraft’s weight and balance, which is required before a flight can leave the gate.
“That issue has been resolved and flights have resumed,” the carrier said in a statement. “We sincerely apologize to our customers for the inconvenience this morning.”
The Federal Aviation Administration said American had requested the ground stop.

Airlines routinely request ground stops, which hold flights at origin, so that destination airports aren’t overwhelmed by flights with nowhere to park when there are disruptions. In addition to technical problems, ground stops are put in place for thunderstorms and other severe weather.
American was operating a smaller schedule on Christmas Eve compared with other days around the Christmas holiday. The carrier didn’t have any cancellations tied to the issue, a spokeswoman said.
Airlines’ patchwork systems of critical technology platforms have gained more attention lately after periods of mass flight cancellations such as Southwest’s meltdown during the 2022 year-end holiday season and Delta’s struggle to recover from the CrowdStrike outage this past summer.
Correction: The ground stop was issued Tuesday. An earlier version misstated the timing.

Don’t miss these insights from CNBC PRO More

The Food and Drug Administration announced that branded tirzepatide, the active ingredient in Eli Lilly’s weight loss drug Zepbound, is no longer in short supply.
That decision will largely prevent compounding pharmacies from making and selling cheaper versions of the drug in the next two to three months. 
It will also leave some patients in limbo, closing a niche market for compounded tirzepatide that patients say helped fill a gap in care for those who say they simply can’t afford to pay out of pocket for Zepbound.

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.
Brendan McDermid | Reuters

The roughly $1,000 monthly price tag of Eli Lilly’s weight loss drug Zepbound put the blockbuster treatment out of reach for Willow Baillies, 29, whose insurance does not cover it.
Baillies, a human resources specialist based in Milwaukee, Wisconsin, has been attempting to lose weight and dealing with chronic autoimmune issues for years, so she turned to a cheaper alternative: a compounded, off-brand version of tirzepatide.

Tirzepatide is the active ingredient in Zepbound and in Eli Lilly’s diabetes counterpart Mounjaro, which are part of a class of highly popular medications called GLP-1s. 
She said compounded tirzepatide has helped change her life dramatically since she began taking it in June, alleviating pain from her autoimmune issues and helping her lose about 52 pounds. She said it costs her around $350 per month.
But soon, compounded versions of tirzepatide could become inaccessible to Baillies and other patients who rely on them. Patients and health-care experts said that could force some consumers to stockpile doses, switch to other treatments, or stop receiving care altogether due to financial constraints. Others could turn to a potentially unsafe method of mixing vials themselves. 
That’s because the Food and Drug Administration on Thursday announced that branded tirzepatide is no longer in short supply — a decision that will largely prevent compounding pharmacies from making and selling cheaper versions of the drug in the next two to three months. 
During FDA-declared shortages, pharmacists can legally make compounded versions of brand-name medications. But drugmakers and some health experts have pushed back against the practice because the FDA does not approve compounded drugs, which are essentially custom-made copies prescribed by a doctor to meet a specific patient’s needs. 

The FDA’s decision, based on the agency’s comprehensive analysis of data, could mean that more patients with insurance coverage will be able to access Zepbound after months of limited supply. It also suggests that Eli Lilly’s multibillion-dollar effort to ramp up manufacturing for tirzepatide is starting to pay off. 
But it will also leave other patients in limbo, closing a niche, lucrative market for compounded tirzepatide that patients say helped fill a gap in care for those who can’t afford to pay out of pocket for Zepbound.
Many insurance plans still don’t cover drugs for weight loss, and some patients said prices under Eli Lilly’s savings program and for its half-priced vial versions are still too high.
“I’ve stockpiled 10 compounded vials at home, so I have at least a year’s worth,” said Baillies, one of six patients CNBC spoke with about compounded tirzepatide. “We’re willing to kind of do anything to have this. It’s not just about looks; it’s about the opportunity it gives us to live our lives to the fullest.” 
Many patients and major trade groups question whether the shortage is truly resolved amid reports of people still struggling to find Eli Lilly’s drugs. 
Some medical professionals raised concerns about whether Eli Lilly can meet demand once more patients come off compounded tirzepatide and others start Zepbound for its newly approved use: obstructive sleep apnea. 
It’s unclear how many people are on compounded tirzepatide, but one trade group estimated in November that there are more than 200,000 prescriptions for compounded versions of its main rival — Novo Nordisk’s weight-loss drug Wegovy — being filled each month. 
“In this current moment, I have confidence that the shortage is over,” said Dr. Shauna Levy, an obesity medicine specialist and medical director of the Tulane Bariatric Center in New Orleans. “Do I think the shortage is over forever? Probably not.” 
Eli Lilly did not immediately respond to a request for comment.

Compounders face deadlines, with some exceptions

The FDA initially declared the tirzepatide shortage over in October. 
But a trade group called the Outsourcing Facilities Association sued days later, claiming the agency made its determination without proper notice and failed to account for continued supply disruptions. That lawsuit pushed the FDA to reconsider and allowed pharmacists to make compounded versions in the meantime. 
In its decision announced Thursday, the FDA concluded based on data from Eli Lilly, patients, providers, compounders, and other sources that “Lilly’s supply is currently meeting or exceeding demand and that, based on our best judgment, it will meet or exceed projected demand.”
The FDA is giving so-called 503A compounding pharmacies until Feb. 18 before it takes enforcement action that would put a halt to their work. The 503A pharmacies make compounded drugs according to individual prescriptions for a specific patient and are largely regulated by states rather than the FDA. 
Meanwhile, pharmacies manufacturing compounded drugs in bulk with or without prescriptions — known as 503B outsourcing facilities — get an additional month, with a deadline of March 19. They are regulated by FDA guidelines. 

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024.
Shelby Knowles | Bloomberg | Getty Images

Those “off-ramp periods are appreciated” because it gives patients time to switch to brand-name tirzepatide, said Tenille Davis, chief advocacy officer for trade group Alliance for Pharmacy Compounding.
But the group’s members are still reporting that “there’s a real lack of availability” of tirzepatide, she said. That trade group represents compounding pharmacies and hybrid pharmacies that also dispense regular drug prescriptions.
Still, 503A pharmacies may be allowed to continue making compounded tirzepatide in certain situations under the law, Davis said. 
That includes when a prescriber determines that a compounded version with certain changes will produce a “significant difference” for a patient. For example, a patient may need a specialized dose or be allergic to the dye in a branded product. 
Davis said that means compounded tirzepatide won’t be completely eliminated in the U.S., but the scale of it will “certainly decrease.”
The legal battle between the FDA and the Outsourcing Facilities Association isn’t over yet, however. On Thursday, the FDA and OFA jointly said they will provide an update in court by Jan. 2 to address the “next steps in this litigation.” They also said if the trade group files a preliminary injunction over the next two weeks, the FDA will not take action against its members for continuing to make compounded tirzepatide until the court resolves the case.
That pending litigation further “adds to the confusion of the status of compounded tirzepatide after February and March,” said Dae Lee, a partner at law firm Frier Levitt who represents pharmacies, none of which were involved in the dispute with the FDA.

Patients look to alternatives

Amanda Bonello has been taking compounded tirzepatide and has launched a petition demanding the FDA support access to compounded GLP-1s.
Courtesy: Amanda Bonello

Many patients who rely on compounded tirzepatide are scrambling to ensure they can continue care. 
That includes Amanda Bonello, 36, an Iowa-based account manager who said she is prediabetic. Bonello said taking compounded tirzepatide over the last two months has helped her lose 26 pounds and normalized her blood sugar levels, allowing her to avoid a diabetes diagnosis. 
She said she “absolutely cannot” afford branded tirzepatide since her insurance does not cover it, so she will consider switching to compounded semaglutide. That is the active ingredient in Wegovy and its diabetes counterpart Ozempic, Novo Nordisk’s two GLP-1s that are still on the FDA’s drug shortage list. 
Many compounding pharmacies make unbranded versions of semaglutide, which has been on the U.S. market — and in short supply — for much longer than tirzepatide. But an end to the shortage may be imminent, with the FDA announcing in late October that all doses of semaglutide are available. 
“If compounded semaglutide goes away as well, then I will be screwed,” Bonello said. She has launched an online petition demanding that the FDA support access to compounded GLP-1s. The petition has gained more than 15,000 signatures in the past month.

Erin Hunt (right,) a patient who has been taking compounded tirzepatide, and her husband Brice.
Courtesy: Erin Hunt

Another patient, Erin Hunt, 31, a communications analyst based in Maryland, said she may eventually switch to the branded version of tirzepatide. 
Hunt started taking compounded tirzepatide in April after struggling to find supply of Zepbound, which she took for one month. It has helped her lose around 55 pounds, experience fewer symptoms from her chronic inflammatory conditions and pursue a healthier diet and exercise. She said she initially paid $300 per month for the compound drug and now pays $350 for a higher dose.
Hunt’s insurance does not cover Zepbound. But she qualifies for Eli Lilly’s savings card program, which allows commercially insured patients without coverage for Zepbound to buy a month’s supply for around $650. Under that program, patients whose commercial insurance plan covers Zepbound can pay as low as $25. 
“I am extremely concerned for what it’s going to cost,” Hunt said. “This medication has literally changed my life, and it’s probably going to benefit me to be on a maintenance dose for life.”
For Jill Skala, 49, a teacher in western Pennsylvania, the FDA’s decision means that she will lose a more affordable option after her insurance drops Zepbound coverage on Jan. 1. 
Her copay for Zepbound has been around $10 per month since she started the drug in March. Skala said she has lost 52 pounds and noticed “profound improvements” in her mental health, sleep and energy levels. She has stockpiled a three-month supply of Zepbound, she said, and will “do the best I can to maintain my weight loss” once that runs out.
“I don’t see myself continuing to get the branded version at this point unless there’s a pathway back through insurance or Eli Lilly drops the price,” Skala said. “I just paid off my student loans. I don’t want to start my medical debt problem here.”

Jill Skala has been taking branded Zepbound since March, but will soon lose insurance coverage for it.
Courtesy: Jill Skala

Other patients may turn to an underground community Reddit users call “the gray market”: People directly purchase powdered tirzepatide or semaglutide peptides for as little as $50 per month from certain vendors, including Chinese manufacturers, and mix that with sterile water at home, creating a solution they can inject under their skin. 
Reddit users say the community establishes protocols for third-party lab testing of peptides to verify their purity and promotes safe mixing and dosing practices. 
But Tulane’s Levy said the method “seems very dangerous,” noting that mixing homemade medications without proper training “could potentially have real consequences.” 
She said it “highlights people’s desperation to treat the disease of obesity, which is being inadequately met by our current insurance status” for drugs such as Zepbound. 

Continuing care

Some compounding pharmacies such as Strive Pharmacy are operating as usual pending more updates to the legal fight. Strive operates nine 503A pharmacies across the U.S., which offer compounded GLP-1s and other services. 
But Strive will largely stop making compounded tirzepatide by the February deadline if nothing further happens, according to Matthew Montes de Oca, the company’s chief clinical officer. He acknowledged that Strive could create compounded versions of the drug for specific prescriptions, such as adding glycine to help prevent muscle deterioration in a patient. 
Compounded tirzepatide with glycine is what Gina Wright’s doctor will prescribe for her so she can continue taking the unbranded version, which she gets from a different pharmacy. Wright, 58, a self-employed business consultant in Colorado who is prediabetic, said she is paying $225 for a five-milligram dose, which she began taking earlier this month. 
She is on her state Medicaid plan, which does not cover Zepbound, so she does not qualify for Eli Lilly’s savings card program. But Wright said she also has sleep apnea, so she is trying to get insurance to cover Zepbound for that purpose.

Gina Wright began taking compounded tirzepatide earlier this month.
Courtesy: Gina Wright

De Oca said compounding individual prescriptions for specific patients will make it harder for Strive to ensure that all of its safety procedures are still in place. Strive typically tests its tirzepatide and semaglutide with a third-party analytical company and conducts a months-long “stability study” to guarantee the quality and safety of the product before creating batches of up to 250 vials, he noted. 
Dr. Mace Scott, the owner and medical director of Chronos Body Health Wellness, said the fate of compounded tirzepatide at his Louisiana-based medical spa will depend on the pharmacies he sources it from and “how they decide to move forward.” His spa relies on both 503A and 503B pharmacies, he said, so some patients may be able to continue compounded tirzepatide with a specialized prescription. 
Scott said he is trying to help some patients get insurance approval for branded tirzepatide. He is recommending that others switch to compounded semaglutide, which is what roughly 75% of Chronos patients are taking, he said. The spa has treated more than 10,000 patients with branded or compounded GLP-1 medications, according to its website.
“It’s kind of a tough road to traverse right now, so we’re trying to figure out what’s best on a patient-by-patient basis,” Scott told CNBC. 
The American Diabetes Association, a nonprofit organization that promotes diabetes research and advocacy, told CNBC it recommends against the use of compounded GLP-1s due to “ongoing concerns” about their safety, quality and efficacy.
It is difficult to discern the quality of the product and its distributor, which poses a potential risk to patients, Joshua Neumiller, the association’s president-elect for health care and education, said in a statement.
Neumiller also pointed to an FDA alert in July about cases of patients measuring and administering incorrect doses of compounded GLP-1s, some of which resulted in adverse events that required hospitalization. 
But Molly B., an interior designer based in New York who asked CNBC to omit her full last name, said compounded GLP-1s are her only option.
She said her insurance denied coverage for brand-name semaglutide twice before she started taking compounded tirzepatide in September. It has helped her lose 23 pounds, she said, and eliminated constant thoughts about food — a game changer for a patient suffering from polycystic ovary syndrome, a hormonal disorder that makes it difficult to lose weight. 
“I have never been able to lose this much weight on my own, and I’ve tried 100 times,” she said. “This has really changed my life, so I would hope that I can continue to get it the way I am now.” More

There’s growing concern that a 25% potential tariff on Canadian imports to the U.S. could be an existential threat to the country’s recovering automotive industry.
President-elect Donald Trump has said he will impose an additional 10% tariff on goods from China and a 25% levy for Canada and Mexico.
Ontario Premier Doug Ford told CNBC any tariffs would be harmful to both sides of the border.

Canadian and American flags fly near the base of the Ambassador Bridge connecting Canada to the U.S. in Windsor, Ontario, Canada, on Wednesday, May 26, 2021.
Cole Burston | Bloomberg | Getty Images

DETROIT — There’s growing concern that President-elect Donald Trump’s plan to impose 25% tariffs on Canadian imports would be an existential threat to the country’s recovering automotive industry.
Potential tariffs on vehicles and automotive parts are particularly alarming for the province of Ontario, the epicenter of Canada’s auto industry. Five automakers — Ford Motor, General Motors, Stellantis, Toyota Motor and Honda Motor — produced 1.54 million light-duty vehicles last year in the province, largely for U.S. consumers.

“It’d be terrible. It’d not only devastate Canadian jobs, it’d devastate American jobs,” Ontario Premier Doug Ford told CNBC during a phone interview.
A tariff is a tax on imports, or foreign goods, brought into the U.S. They are paid for by companies, which some fear would simply pass any additional costs on to consumers.
Ford, who said he has not spoken with Trump directly, argued that any tariffs would be harmful to both sides of the border.
He said raw materials and parts routinely pass across the border multiple times before being used in the final assembly of a vehicle. Tariffs, he warned, would increase prices, which could then slow production and eliminate jobs.
“We have a trade agreement right now. Things have been working,” Ford said. “I’ve said it publicly: I’d love to do a bilateral trade deal with the U.S. And Mexico wants a trade deal, we’ll do a bilateral trade deal with Mexico. But Mexico, if they want a seat at the table, they have to follow the rules.”

Ontario premier Doug Ford answers questions from reporters as he hosts the Fall meeting of Canada’s premiers in Mississauga, Ontario, Canada December 16, 2024.
Carlos Osorio | Reuters

Trump has said he will impose an additional 10% tariff on goods from China and a 25% levy for Canada and Mexico, though he has offered few details, such as if there would be exceptions. He has he said plans to invoke “national security” concerns to enact such hikes, rather than seeking congressional approval, saying illegal immigration and the illicit drug trade are causing concerns on the border, justifying the tariffs.
Putting tariffs on components could add $600 to $2,500 per vehicle on parts from Mexico, Canada and China, according to estimates in a Wells Fargo analyst note. Prices on vehicles assembled in Mexico and Canada — which account for about 23% of vehicles sold in the U.S. — could rise $1,750 to $10,000.
Such tariffs and increased costs would add to problems for embattled Canadian Prime Minister Justin Trudeau, as he fends off calls for his resignation.

Ontario: Canada’s auto capitol

Ontario recently launched a multimillion-dollar ad campaign in the U.S. to promote its role as a key trading partner and “ally to the North.”
Ontario, as a province, is the third-largest trading partner for the U.S., including the top foreign trade partner for 17 states, according to Ford, the premier. He points out that trade between Ontario — as well as broader Canada with the U.S. — is much more evenly split than it is with Mexico, especially when removing the oil Canada sends to the U.S.

Canada’s Prime Minister Justin Trudeau addresses the Liberal party caucus meeting in Ottawa, Ontario, Canada December 16, 2024. 
Blair Gable | Reuters

Canadian exports of auto parts came in at $23.5 billion in 2023, while exports of light vehicles totaled $53.5 billion. Imports totaled $47.5 billion and $70.4 billion, respectively, according to Canada-based DesRosiers Automotive Consultants. Of those, the U.S. accounts for 95.3% of Canada’s total auto exports and 57.7% of its overall auto imports.
“Anything that kind of disrupts that balance is going to affect both sides of the border,” said Flavio Volpe, head of the Canadian Automotive Parts Manufacturers’ Association. “The best tariff level for Canadian and American auto parts suppliers is zero.”
Volpe argues a double-digit tariff would be “existential,” with ripple effects into the U.S. automotive industry. As an example, he pointed to 2022, when Canadian truck drivers blocked the Ambassador Bridge between Detroit and Windsor, Ontario, in Canada — the busiest border bridge between the countries — disrupting manufacturing for several automakers in the U.S.
Toyota is the top-producing automaker in Canada, at roughly 526,000 units in 2023, followed by Honda at nearly 378,500 vehicles. GM, once the largest producer in Canada at more than 1 million vehicles, is now one of the smallest manufacturers of light-duty vehicles in the region.

Industry on the mend

The Canadian automotive industry is on an upswing following a decades-long decline that escalated during the coronavirus pandemic.
Light-duty vehicle production in Canada hit 1.54 million vehicles last year, up from a recent low of 1.1 million in 2021, but still a 47% decline from the country’s peak of 2.9 million in 2000, according to industry data provided by the Global Automakers of Canada trade association.
“The industry, like the American industry, has been challenged recovering from the pandemic. We’re still not there from a sales and production point of view, but we have been recovering,” said David Adams, president of the Global Automakers of Canada, which represents the interest of 16 non-U.S. based automakers.
The uptick comes despite two large assembly plants in Ontario, owned by Ford and Stellantis, existing in limbo, as the factories don’t currently have vehicles to produce. Thousands of workers have been laid off as a result of the lack of production.
Much of the uncertainty was caused by the automotive industry’s transition to all-electric vehicles, as adoption of EVs has not occurred as quickly as expected. Trump also has vowed to remove subsidies for purchasing EVs, which have assisted in spurring sales while federal benefits still exist.
“There is profound concern about the Canadian automobile industry as much because it’s not clear what direction to go,” said Charlotte Yates, president of the Automotive Policy Research Centre and professor emeritus at McMaster University. “There’s a series of public policy changes as well as political attitudinal changes, and, of course, the threat of tariffs really rattling the industry in Canada.”
Ford, Ontario’s premier, said the U.S. and Canada should be working together, as they have been for decades.
“We should be focusing on China and Mexico, not on its closest ally in the entire world,” Ford said. “Let’s build a fortress, an American–Canadian fortress against the rest of the world. We can’t be stopped if we if we stick together.”

Don’t miss these insights from CNBC PRO More

The Consumer Financial Protection Bureau on Monday sued Walmart and work-scheduling platform Branch Messenger for allegedly forcing delivery drivers to use poorly managed and costly deposit accounts in order to get paid.
The lawsuit alleges that, since 2021, Walmart and Branch opened Branch accounts for drivers and then deposited drivers’ pay into these accounts without the drivers’ consent.
The lawsuit is the latest in a slew of actions by the CFPB against companies for mishandling consumer and worker financial accounts.

A Walmart truck pulls out of a Walmart Distribution Center in Hurricane, Utah, on May 30, 2024.
George Frey | Afp | Getty Images

The Consumer Financial Protection Bureau filed a complaint Monday against Walmart and work-scheduling platform Branch Messenger for allegedly forcing delivery drivers to use poorly managed and costly deposit accounts in order to get paid.
“Walmart made false promises, illegally opened accounts, and took advantage of more than a million delivery drivers,” CFPB Director Rohit Chopra said in a press release. “Companies cannot force workers into getting paid through accounts that drain their earnings with junk fees.”

The lawsuit alleges that, since 2021, Walmart and Branch opened Branch accounts for more than one million drivers part of the Spark Driver Program, Walmart’s platform for gig economy workers to accept and schedule “last mile” deliveries, and then deposited drivers’ pay into these accounts without their consent.
The company allegedly told drivers that they would be fired if they did not want to use the Branch accounts and misled drivers about when they could access their earnings. When drivers did use the platform, they allegedly faced numerous delays or fees if they needed to transfer the money into a different account, which resulted in more than $10 million in “junk fees.”
Walmart disputed the agency’s allegations.
“The CFPB’s rushed lawsuit is riddled with factual errors and contains exaggerations and blatant misstatements of settled principles of law,” a Walmart spokesperson wrote in a statement to CNBC. “The CFPB never allowed Walmart a fair opportunity to present its case during their rushed investigation.”
The CFPB also accused Branch of failing to investigate alleged errors, failing to provide certain disclosures, failing to maintain records, failing to follow through on stop payment requests and illegally requiring consumers to waive their rights under the law.

“Branch strongly disagrees with the lawsuit filed today by the CFPB, which misstates the law and facts, and includes intentional omissions to mask the Bureau’s clear overreach,” a representative from Branch wrote in a statement to CNBC.
The lawsuit is the latest in a slew of actions the CFPB has taken against companies for mishandling consumer and worker financial accounts. The bureau previously sued Comerica Bank over allegations that it failed to administer a federal benefits program and charged illegal fees on prepaid debit cards.
Most recently, the CFPB filed a complaint against the operator of the Zelle payments network, as well as JPMorgan Chase, Bank of America and Wells Fargo, alleging that the firms failed to properly investigate fraud complaints or give victims reimbursement. The lawsuit claims customers have lost more than $870 million since the launch of Zelle in 2017.

Don’t miss these insights from CNBC PRO More